You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 16 No. 5, May 1967 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (34)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Creatine Phosphokinase in Neuromuscular Disease

Patients and Families

Ikuo Goto, MD, PhD; Henry A. Peters, MD; Hans H. Reese, MD

Arch Neurol. 1967;16(5):529-535.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

MANY investigations of serum glutamic oxalacetic transaminase (SGOT),1 glutamic pyruvic transaminase (GPT), aldolase,2-6 and lactic dehydrogenase (LDH)6 have been reported in the diagnostic and genetic studies of progressive muscular dystrophy. Elevation of these enzymes, however, is not specific for progressive muscular dystrophy and may occur in other conditions7-10 such as impaired liver function. Assay of creatine phosphokinase (CPK) has also been used for the diagnosis of progressive muscular dystrophy10-14 and for the detection of carrier females in families with Duchenne-type pseudohypertrophic muscular dystrophy.15-17

Since our CPK findings for the detection of carriers are at variance with several of the papers cited, we wish to present our data on CPK levels in muscular dystrophy families. Moreover, we will demonstrate that an elevated CPK is not specific for muscular dystrophy since modest CPK elevation is noted also in several neuromuscular disorders.

Methods

Most blood samples were . . . [Full Text PDF of this Article]


Author Affiliations

Madison, Wis

From the Department of Neurology, University of Wisconsin Medical School, Madison, Wis. Dr. Goto is a fellow of the Muscular Dystrophy Association of America, Inc. His present address is Second Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.


Footnotes

Submitted for publication July 16, 1966; accepted Dec 3.

Reprint requests to Department of Neurology, N & R Hospital, 1954 E Washington Ave, Madison, Wis 53714 (Dr. Peters).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1967 American Medical Association. All Rights Reserved.